Opiates and dopamine (DA) play key roles in learning and memory in humans and animals. Although interactions between these neurotransmitters have been found, their functional roles remain to be fully elucidated, and their dysfunction may contribute to human diseases and addiction. Here we investigated the interactions of morphine and dopaminergic neurotransmitter systems with respect to learning and memory in rhesus monkeys by using the Wisconsin General Test Apparatus (WGTA) delayed-response task. Morphine and DA agonists (SKF-38393, apomorphine and bromocriptine) or DA antagonists (SKF-83566, haloperidol and sulpiride) were co-administered to the monkeys 30 min prior to the task. We found that dose-patterned co-administration of morphine with D1 or D2 antagonists or agonists reversed the impaired spatial working memory induced by morphine or the compounds alone. For example, morphine at 0.01 mg/kg impaired spatial working memory, while morphine (0.01 mg/kg) and apomorphine (0.01 or 0.06 mg/kg) co-treatment ameliorated this effect. Our findings suggest that the interactions between morphine and dopaminergic compounds influence spatial working memory in rhesus monkeys. A better understanding of these interactive relationships may provide insights into human addiction.
AbstrAct
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INtrODUctION
Working memory refers to the short-term storage and manipulation of information in memory, and is thought to be dependent upon the prefrontal cortex (PFC) [1] . The PFC mediates executive functions essential for planned and goal-directed behaviors and is modulated by several neurotransmitters, especially dopamine (DA) [2] . Impairment of executive functions, potentially by neurochemical imbalances, may cause psychiatric and neurological disorders, including mood and anxiety disorders, schizophrenia, and/ or drug addiction [3] .
In addition to the dopaminergic influences on executive functions, opiate agonists such as morphine have been found to induce deficits in working memory and episodic memory in humans [4] [5] [6] . An acute dose of morphine in palliative care patients has been reported to cause both anterograde and retrograde memory impairment [7] . Our previous work also shows that heroin, another opiate agonist, causes deficits in both map and landmark working memory in addicted humans [8] . Similar findings have also been reported in animal models. For example, Schulze and Paule (1991) [9] found that morphine given to rhesus monkeys 15 min prior to a battery of complex food-reinforced operant tasks, .
All told, the close proximity of the opiate and dopaminergic neurotransmitter systems and their related roles in learning and memory, especially in the PFC, suggest that interactions between these two systems may exist and contribute to executive functions in animals and humans.
Although similar interactions of the opiate and dopaminergic systems have been widely studied in rodents, few have been performed in primates. The rhesus monkey (Macaca mulatta) provides a useful model to evaluate these interactions since it has closer evolutionary ties to humans and a higher degree of intelligence and subsequent executive functions than rodents.
The current study was performed to investigate the interaction between opioid and dopaminergic neurotransmitters in learning and memory. The effects of single or coadministration of morphine and DA receptor (D1 and D2 family) agonists/antagonists were evaluated in regards to spatial working memory in the rhesus monkey. The Wisconsin General Test Apparatus (WGTA) delayed-response task, a marker task for working memory, was used to evaluate the monkeys' spatial working memory [15] . To prevent the development of opiate tolerance during the experiment, low doses of morphine and dopaminergic compounds were administered and the monkeys were allowed to recover from the drug treatments before subsequent injections.
MAtErIALs AND MEtHODs
Animals
Four male rhesus monkeys (Macaca mulatta) (named KunKun, LaLa, DeDe, and XiDie) from the breeding colony at the Kunming Institute of Zoology were used. They were 8.0 ± 0.7 years and weighed 6.8 ± 0.3 kg at the onset of the experiments. After the experiments were finished, the average weight was 9.0 ± 0.8 kg. One monkey was replaced because his performance scores were too high to discriminate the effects of the study after a one-year-test, therefore the experimental group included only three monkeys. 
behavioral training Procedures
Each monkey had ~1 000 training trials before the pharmacological experiments (30 trials for each workday). Each day, the peanuts were placed into the right or left well for 15 trials. The placement of the peanut was quasi-randomly arranged [16] . Only when monkeys reached this stable criterion was the pharmacological study started, and the effect of each drug was tested at all delay times (A-E) for each monkey.
The average B-delay length for the monkeys was 11.3 ± 6.3 s at the beginning of the experiments, and 20.5 ± 6.1 s when the experiments ended.
Drug Administration and behavioral testing Procedures
A single-blind procedure was used during testing. The same experimenter gave the injections and performed the delayed-response experiments without knowing on which day and what compounds were given to the monkey.
On the first day of each test period, the monkeys were intra-muscularly (i.m.) injected with 0.9% saline (0.05 mL/ kg body weight). After 30 min, the monkeys were tested in the delayed-response task. These responses were used as the baseline for each study and were subsequently marked as pre-treatment.
On the next (second) day, the monkeys were injected i.m. with different compounds (0.05 mL/kg body weight, according to the blind procedure) 30 min before the test.
Compounds were administered either singly or in tandem with morphine. For co-administration, the two drugs were successively injected 30 min before the test. All compounds were administered according to this protocol except for bromocriptine because it is insoluble in water. One hour before the test, bromocriptine was placed into a piece of banana for oral administration, and for morphine co-administration the morphine was injected i.m. 30 min later. After 30 min, the monkey underwent 30 trials (five delay lengths, semirandomly distributed), and the performance was indicated as: total correct responses/30 ×100%.
Follow-up tests using the delayed-response task were usually conducted on the next day to determine if the monkey's performance had recovered to its normal level. The monkeys were not given any injection before these measurements. These measurements were marked as post-treatment.
Typically, the monkey was injected with saline on Monday followed by the drugs on the next day. Then he was allowed to recover for a few days which meant he returned to a 93% correct response rate in the task before the next drug treatment. For some drugs with low doses and no effects, the next round of testing was conducted on Thursday following recovery.
During the testing period, the drug type or drug com- 
rEsULts
Effects of single Morphine treatment on spatial Working
Memory in rhesus Monkeys
The monkeys showed relatively stable baselines in WGTA 
D1/D2 Agonist Apomorphine
Apomorphine, at the dose range used, did not have any effect on spatial working memory (Table 1, Fig. 1B ), or on gross behaviors. Therefore, the medium (0.01 mg/kg) and the high doses (0.06 mg/kg) were continued in the morphine + apomorphine co-administration experiment.
Apomorphine + morphine had no effect on spatial working memory, but improved the spatial working memory deficits induced by 0.01 mg/kg morphine alone (Fig. 1B) .
D2 Agonist bromocriptine
Bromocriptine treatment decreased the working memory Therefore, the dose of SKF-83566 was not increased beyond 0.06 mg/kg. All three monkeys became excited after co-treatment with SKF-83566 (0.06 mg/kg) and morphine but were able to finish the delayed-response task. In detail, single treatment with sulpiride (0.001, 0.01, and 0.1 mg/kg) impaired spatial working memory without causing a change in behavior (Table 1, Fig. 2C ). Sulpiride 
D2 Antagonist Haloperidol
DIscUssION
In the current study, the spatial working memory of rhesus monkeys was tested using the WGTA delayed-response task. We found that morphine impaired the spatial working memory of the monkeys, but it depended on the dose.
When the monkeys were co-treated with morphine and the DA receptor agonists SKF-38393, apomorphine and bromocriptine, the memory impairment caused by individual treatment was reversed in most instances. Similarly, when the monkeys were co-treated with the DA receptor antagonists SKF-83566, haloperidol and sulpiride, reversal of memory impairment was found, and it also depended on the drug and the dose.
The present finding that morphine caused an impairment in working memory is consistent with previous studies, including ours and those by other researchers [17, 18] .
The low dose of morphine (0.001 mg/kg) had no effect on working memory in any trials (5 separate injections). However, high doses of morphine caused sedation in addition to impairing working memory. This sedation may be attributed to the increases in DA levels produced by morphine administration, given that DA acts as a sedative.
DA activity in the PFC plays an important role in working memory. For example, Watanabe and Kodama found, using in vivo microdialysis, a significant increase in the extracellular DA levels in the dorsolateral PFC in monkeys performing a delayed-alternation task, a typical working memory paradigm [19] . Therefore changes in PFC DA levels are thought to influence working memory. The findings presented here showed that single treatment with bromocriptine, a D2 receptor agonist, impaired spatial working memory in rhesus monkeys.
On the other hand, the D1 receptor agonist SKF-38393 and apomorphine, a D1 and D2 receptor agonist, did not affect working memory in the monkeys.
Cai and Arnsten (1997) [20] found that low doses of the Apomorphine is known to stimulate autoreceptors which signal negative feedback that may inhibit the synthesis and release of DA. However, apomorphine also has a high binding-affinity for D2 receptors, which suggests that D2 receptor may play a role in the similar working memory impairment found with apomorphine and bromocriptine treatment. In the current study, a slight impairment of working memory was found in apomorphine at 0.01 mg/kg, but the difference was not significant.
In addition to the involvement of D1 receptors in working memory, D2 receptors have been found to act on the functional circuitry of working memory [21] . In the current study, the D2 receptor agonist bromocriptine impaired working memory, and so did the D2 receptor antagonists haloperidol and sulpiride, which caused dose-dependent deficits. found that the μ-opioid receptor forms a hetero-oligomer complex with the D1 receptor, and neurons expressing both receptors occur in the cortex and striatum [22] . A previous study also showed reduced μ-opioid receptor expression in striatal patches from D1 receptor-null mice [23] . This might 
